467 related articles for article (PubMed ID: 32329830)
1. m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1.
Ma XX; Cao ZG; Zhao SL
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3565-3571. PubMed ID: 32329830
[TBL] [Abstract][Full Text] [Related]
2. The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.
Miao W; Chen J; Jia L; Ma J; Song D
Biochem Biophys Res Commun; 2019 Aug; 516(3):719-725. PubMed ID: 31253399
[TBL] [Abstract][Full Text] [Related]
3. Progression of Thyroid Carcinoma Is Promoted by the m6A Methyltransferase METTL3 Through Regulating m
Wang K; Jiang L; Zhang Y; Chen C
Onco Targets Ther; 2020; 13():1605-1612. PubMed ID: 32158230
[TBL] [Abstract][Full Text] [Related]
4. The m6A methyltransferase METTL3 promotes the stemness and malignant progression of breast cancer by mediating m6A modification on SOX2.
Xie J; Ba J; Zhang M; Wan Y; Jin Z; Yao Y
J BUON; 2021; 26(2):444-449. PubMed ID: 34076991
[TBL] [Abstract][Full Text] [Related]
5. The m6A methyltransferase METTL3 aggravates the progression of nasopharyngeal carcinoma through inducing EMT by m6A-modified Snail mRNA.
Yu X; Zhao H; Cao Z
Minerva Med; 2022 Apr; 113(2):309-314. PubMed ID: 32512975
[TBL] [Abstract][Full Text] [Related]
6. METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
Meng QZ; Cong CH; Li XJ; Zhu F; Zhao X; Chen FW
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4328-4336. PubMed ID: 32373970
[TBL] [Abstract][Full Text] [Related]
7. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
8. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
Chen Y; Pan C; Wang X; Xu D; Ma Y; Hu J; Chen P; Xiang Z; Rao Q; Han X
Theranostics; 2021; 11(16):7640-7657. PubMed ID: 34335955
[No Abstract] [Full Text] [Related]
9. METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3.
Yi J; Peng F; Zhao J; Gong X
Sci Rep; 2023 Oct; 13(1):17292. PubMed ID: 37828232
[TBL] [Abstract][Full Text] [Related]
10. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
[TBL] [Abstract][Full Text] [Related]
11. Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
Liu T; Yang S; Sui J; Xu SY; Cheng YP; Shen B; Zhang Y; Zhang XM; Yin LH; Pu YP; Liang GY
J Cell Physiol; 2020 Jan; 235(1):548-562. PubMed ID: 31232471
[TBL] [Abstract][Full Text] [Related]
12. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
Ma Z; Li Q; Liu P; Dong W; Zuo Y
Cell Biol Int; 2020 Dec; 44(12):2524-2531. PubMed ID: 32869897
[TBL] [Abstract][Full Text] [Related]
13. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway.
Cui X; Wang Z; Li J; Zhu J; Ren Z; Zhang D; Zhao W; Fan Y; Zhang D; Sun R
Cell Prolif; 2020 Mar; 53(3):e12768. PubMed ID: 31967701
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA.
Chen WW; Qi JW; Hang Y; Wu JX; Zhou XX; Chen JZ; Wang J; Wang HH
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4263-4270. PubMed ID: 32373962
[TBL] [Abstract][Full Text] [Related]
15. METTL3-mediated m6A modification of pri-miR-148a-3p affects prostate cancer progression by regulating TXNIP.
Li G; Liu J; Wang Y; Liu H; Fu J; Zhao Y; Huang Y
Environ Toxicol; 2023 Oct; 38(10):2377-2390. PubMed ID: 37449729
[TBL] [Abstract][Full Text] [Related]
16. Genetic and pharmacological inhibition of METTL3 alleviates renal fibrosis by reducing EVL m6A modification through an IGF2BP2-dependent mechanism.
Ni WJ; Zhou H; Lu H; Ma NN; Hou BB; Li W; Kong FX; Yu JT; Hou R; Jin J; Wen JG; Zhang T; Meng XM
Clin Transl Med; 2023 Aug; 13(8):e1359. PubMed ID: 37537731
[TBL] [Abstract][Full Text] [Related]
17. METTL3 promotes prostate cancer progression by regulating miR-182 maturation in m6A-dependent manner.
Wang D; Wang X; Huang B; Zhao Y; Tu W; Jin X; Shao Y; Zhu Y; Lu G
Andrologia; 2022 Aug; 54(7):1581-1591. PubMed ID: 35413135
[TBL] [Abstract][Full Text] [Related]
18. METTL3-Mediated m
Mao Y; Li W; Weng Y; Hua B; Gu X; Lu C; Xu B; Xu H; Wang Z
Cell Transplant; 2022; 31():9636897221122997. PubMed ID: 36073002
[TBL] [Abstract][Full Text] [Related]
19. METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism.
Xie W; Ma LL; Xu YQ; Wang BH; Li SM
Biochem Biophys Res Commun; 2019 Oct; 518(1):120-126. PubMed ID: 31405565
[TBL] [Abstract][Full Text] [Related]
20. m6A-modified circABCC4 promotes stemness and metastasis of prostate cancer by recruiting IGF2BP2 to increase stability of CCAR1.
Huang C; Xu R; Zhu X; Jiang H
Cancer Gene Ther; 2023 Oct; 30(10):1426-1440. PubMed ID: 37563361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
